Art. -Nr.: HY-112654

GCN2iB

63 Cited Publications

Kundenbewertung

Based on 63 publication(s) in Google Scholar

GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC₅₀ of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 2183470-12-2
Formel: C₁₈H₁₂ClF₂N₅O₃S
Molecular Weight:451.83

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

GCN2iB Chemical Structure

CAS. Nr.: 2183470-12-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (63)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

GCN2

2.4 nM (IC₅₀)

GPX4

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen :

GPX1
GPX4

In Vitro

GCN2iB (1 μmol/L) potently inhibits recombinant GCN2 with an IC₅₀ of 2.4 nmol/L, and exhibits high kinase selectivity, showing only extremely low off-target inhibitory activity in a screening panel containing 468 kinases^[1].
GCN2iB (10^-9-10^-5 M; 72 h) enhances the antiproliferative effect of ASNase in GCN2-WT MEF cells, but shows no such effect in GCN2-KO MEF cells, confirming its inhibitory activity targeting GCN2^[1].
GCN2iB (1 μmol/L; 72 h) sensitizes CCRF-CEM, MV-4-11 and SU.86.86 cells to the antiproliferative effect induced by ASNase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

GCN2-WT MEF cells
Concentration:

10^-9-10^-5 M
Incubation Time:

72 h
Result:

Exhibited no antiproliferative effect when combined with ASNase in GCN2-KO MEF cells.
Robustly reduced viability of cells when combined with ASNase in GCN2-WT MEF cells.

In Vivo

GCN2iB (10 mg/kg; twice daily; for 7 consecutive days) acts synergistically with 1,000 U/kg ASNase to potently inhibit the growth of CCRF-CEM acute lymphoblastic leukemia (ALL) xenografts in mice, with a statistically significant interaction (P = 0.0007)^[1].
GCN2iB (10 mg/kg; twice daily; 3 days per week; for 28 consecutive days) acts synergistically with 1,000 U/kg ASNase to improve the survival rate of mice with disseminated MOLT-3 acute lymphoblastic leukemia (ALL)^[1].
GCN2iB (3 mg/kg; i.p.; once every other day; for 6 consecutive weeks) improves cardiac systolic function in diabetic mice induced by high-fat diet combined with Streptozotocin (HY-13753), increases left ventricular ejection fraction by 34.7%, and simultaneously reduces fasting blood glucose, myocardial lipid accumulation, oxidative stress and fibrosis^[2].
GCN2iB (3 mg/kg; intraperitoneal injection; once every 2 days; for 6 consecutive weeks) improves cardiac systolic function in db/db mice, increases left ventricular ejection fraction by 14.5%, while reducing fasting blood glucose, decreasing myocardial lipid accumulation and alleviating oxidative stress^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SCID^[1]
Dosage:

10 mg/kg; co-administered with 1,000 U/kg ASNase
Administration:

twice daily; daily; 7 days
Result:

Did not significantly affect tumor growth (P = 0.99).
Elicited potent antitumor activity (P = 0.0002) with synergistic effects (main effect of ASNase, P = 0.0053; main effect of GCN2iB, P = 0.0006; interaction effect, P = 0.0007) when combined with ASNase.
Achieved a tumor growth inhibition resulting in a treatment over control (T/C) value significantly lower than vehicle, ASNase alone, or GCN2iB alone when combined with ASNase.

Animal Model:

C57BL/6J (male; diabetic cardiomyopathy induced by 8 weeks of high-fat diet + intraperitoneal streptozotocin injection, fasting blood glucose ≥ 11.1 mmol/L)^[2]
Dosage:

3 mg/kg
Administration:

i.p.; every other day; 6 weeks
Result:

Decreased fasting blood glucose to 11.18 mmol/L.
Decreased body weight to 28.94 g.
Increased left ventricular ejection fraction to 70.41%.
Increased heart weight to body weight ratio.
Decreased myocardial fibrosis, myocyte cross-sectional area, and cardiac triglyceride levels.
Decreased mRNA levels of hypertrophic/fibrotic genes (ANP, BNP, β-MHC, Calm3, Collagen-I, Collagen-III) and lipid metabolism-related genes (CD36, Fasn, Plin4, Plin2, Pparγ, SCD1, Srebp1c).
Decreased myocardial 3'-NT, 4-HNE, and superoxide levels.
Upregulated antioxidative genes (Gpx1/4/7, Gstp1/2, Mt1, Prdx2, Trx2) and proteins (GPX4, PRDX2, TRX2).
Decreased protein expression of ANP, FAS, and CIDEA.
Increased myocardial phosphocreatine and taurine levels.
Upregulated oxidative phosphorylation, glycolysis/gluconeogenesis, proteasome, and amino acid biosynthesis pathway genes.
Downregulated hypertrophic cardiomyopathy, dilated cardiomyopathy, and PPAR signaling pathway genes associated with disease progression.

Animal Model:

leptin receptor deficient (db/db) (male; spontaneous type 2 diabetes due to leptin receptor deletion)^[2]
Dosage:

3 mg/kg
Administration:

i.p.; every other day; 6 weeks
Result:

Decreased fasting blood glucose to 9.64 mmol/L.
Decreased body weight to 44.67 g.
Decreased heart weight to 145.7 mg.
Increased left ventricular ejection fraction to 84.05%.
Decreased cardiac triglyceride, 3'-NT, and 4-HNE levels.
Decreased mRNA levels of hypertrophic/fibrotic genes (β-MHC, BNP, Calm3, Collagen-I, Collagen-III) and lipid metabolism-related genes (Fasn, Srebp1c).
Increased mRNA levels of oxidative phosphorylation genes (Atcg1, Atp5d, Atp5j1, Ndufa8, Ndufs6).
Decreased protein expression of ANP, FAS, CD36, and Cidea.
Increased protein expression of GPX4, PRDX2, and TRX2.

Chemical Information

CAS. Nr. 2183470-12-2
Appearance Solid
Molecular Weight 451.83
Formel C₁₈H₁₂ClF₂N₅O₃S
Color Off-white to light yellow
SMILES

O=S(C1=CC(Cl)=CN=C1OC)(NC2=CC=C(F)C(C#CC3=CN=C(N)N=C3)=C2F)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (63)

All IPWBOthers

Sort by:

Journal Impact Factor

Cell

Optogenetics-enabled discovery of integrated stress response modulators. [Abstract]

2025 Sep 4;188(18):4950-4967.e22. PMID: 40651473
Cell Metab

The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid insufficiency. [Abstract]

2023 Dec 5;35(12):2216-2230.e8. PMID: 37979583

GCN2iB purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Dec 5;35(12):2216-2230.e8. [Abstract]

FBXO22-WT and FBXO22-T127A-KI 293T-Endo-FLAG-FBXO22 cells were deprived of amino acids in the presence or absence of 1 μM GCN2iB and subjected to IP with an anti-FLAG antibody, followed by WB analysis of the indicated proteins.

GCN2iB purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Dec 5;35(12):2216-2230.e8. [Abstract]

293T and HeLa cells deprived of amino acids for the indicated times were treated with or without 1 μM GCN2iB, followed by WB analysis of the indicated proteins.

GCN2iB purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Dec 5;35(12):2216-2230.e8. [Abstract]

HeLa-Endo-Flag-FBXO22 cells were cultured in normal medium or amino-acidfree medium containing DMSO or 1 μM GCN2iB for 60 min, then subjected to Duolink. PLA assay with anti-Flag and anti-mTOR antibodies (top). PLA dots per cell (mean ±SEM) from n = 8 images were calculated (bottom).

GCN2iB purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Dec 5;35(12):2216-2230.e8. [Abstract]

293T-Endo-HA-mTOR cells were treated with 100 ng/mL borrelidin (Bor) or 200 ng/mL halofuginone (HF) in the presence or absence of 1 μM GCN2iB for 4 h, followed by WB analysis of the indicated proteins.

GCN2iB purchased from MedChemExpress. Usage Cited in: Cell Metab. 2023 Dec 5;35(12):2216-2230.e8. [Abstract]

293T-Endo-Flag-FBXO22 cells were treated with 200 ng/mL halofuginone (HF) in the presence or absence of 1 μM GCN2iB for 4 h, and subjected to IP with an anti-Flag antibody, followed by WB analysis of the indicated proteins.
Cell Metab

GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. [Abstract]

2022 Aug 2;34(8):1151-1167.e7. PMID: 35839757
Nat Methods

Decoding post-transcriptional regulatory networks by RNA-linked CRISPR screening in human cells. [Abstract]

2025 Jun;22(6):1237-1246. PMID: 40442371
Nat Cancer

Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. [Abstract]

2022 Nov;3(11):1386-1403. PMID: 36411320
Nat Metab

The unique catalytic properties of PSAT1 mediate metabolic adaptation to glutamine blockade. [Abstract]

2024 Aug;6(8):1529-1548. PMID: 39192144
Cancer Res

Caloric Restriction Enhances the Efficacy of Anti-Androgen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation. [Abstract]

2025 Aug 8. PMID: 40779415
Nat Commun

Context-dependent translation inhibition as a cancer therapeutic modality. [Abstract]

2026 Feb 24;17(1):1963. PMID: 41735331
Nat Commun

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade. [Abstract]

2023 Aug 8;14(1):4758. PMID: 37553341
Cell Discov

Selective and competitive functions of the AAR and UPR pathways in stress-induced angiogenesis. [Abstract]

2021 Oct 26;7(1):98. PMID: 34697290
Mol Cell

BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival. [Abstract]

2025 Jul 3;85(13):2581-2596.e6. PMID: 40555234
Mol Cell

eEF2K regulates pain through translational control of BDNF. [Abstract]

2025 Feb 20;85(4):756-769.e5. PMID: 39694034
Mol Cell

eIF3d controls the persistent integrated stress response. [Abstract]

2023 Sep 21;83(18):3303-3313.e6. PMID: 37683648
Nat Chem Biol

A compendium of kinetic modulatory profiles identifies ferroptosis regulators. [Abstract]

2021 Jun;17(6):665-674. PMID: 33686292
Adv Sci (Weinh)

Overcoming Cancer Persister Cells by Stabilizing the ATF4 Promoter G-quadruplex. [Abstract]

2024 Jul 12:e2401748. PMID: 38994891
Chem Eng J

2025 Feb 1.
Clin Cancer Res

A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. [Abstract]

2024 Aug 15;30(16):3603-3621. PMID: 38864850
Cell Death Discov

Activating GCN2 and subsequently the Unfolded Protein Response with the small oral molecule NXP800 delays tumor growth in osteosarcoma. [Abstract]

2026 Feb 5;12(1):94. PMID: 41644942
Cell Death Discov

Integrated stress response is involved in the 24(S)-hydroxycholesterol-induced unconventional cell death mechanism. [Abstract]

2022 Oct 4;8(1):406. PMID: 36195595
Environ Int

Mitochondrial ROS-associated integrated stress response is involved in arsenic-induced blood-testis barrier disruption and protective effect of melatonin. [Abstract]

2025 Mar:197:109346. PMID: 39999483
Environ Int

Mitochondrial ROS-mediated ribosome stalling and GCN2 activation are partially involved in 1-nitropyrene-induced steroidogenic inhibition in testes. [Abstract]

2022 Jul 14;167:107393. PMID: 35843074
Antioxidants (Basel)

Genetic and Pharmacological Inhibition of GCN2 Ameliorates Hyperglycemia and Insulin Resistance in Type 2 Diabetic Mice. [Abstract]

2022 Aug 16;11(8):1584. PMID: 36009303
Antioxidants (Basel)

Inhibition of GCN2 Alleviates Cardiomyopathy in Type 2 Diabetic Mice via Attenuating Lipotoxicity and Oxidative Stress. [Abstract]

2022 Jul 16;11(7):1379. PMID: 35883870
Cell Rep

SLC7A5 is required for cancer cell growth under arginine-limited conditions. [Abstract]

2025 Jan 3;44(1):115130. PMID: 39756034
Cell Rep

Stress-induced perturbations in intracellular amino acids reprogram mRNA translation in osmoadaptation independently of the ISR. [Abstract]

2022 Jul 19;40(3):111092. PMID: 35858571
Cell Syst

GCN2 adapts protein synthesis to scavenging-dependent growth. [Abstract]

2022 Feb 16;13(2):158-172.e9. PMID: 34706266
Sci Signal

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]

2024 Nov 26;17(864):eadp1375. PMID: 39591412
Cells

2026 Jan 16;15(2):164.
EMBO Rep

Amino acid starvation-induced LDLR trafficking accelerates lipoprotein endocytosis and LDL clearance. [Abstract]

2022 Feb 3;23(3):e53373. PMID: 34994492
Int J Mol Sci

Lysine Deprivation Regulates Npy Expression via GCN2 Signaling Pathway in Mandarin Fish (Siniperca chuatsi). [Abstract]

2022 Jun 16;23(12):6727. PMID: 35743178
ACS Omega

Involvement of Integrated Stress Response in Drug-Induced Secondary Dystonia. [Abstract]

2025 Oct 17;10(42):50208-50217. PMID: 41179162
iScience

2025 Nov 30.
FASEB J

Cholic acid exposure during late pregnancy causes placental dysfunction and fetal growth restriction by reactive oxygen species-mediated activation of placental GCN2/eIF2α pathway. [Abstract]

2023 Mar;37(3):e22820. PMID: 36801982

GCN2iB purchased from MedChemExpress. Usage Cited in: FASEB J. 2023 Mar;37(3):e22820. [Abstract]

GCN2iB (1 μM; 12 h) significantly inhibits Cholic acid (CA)-induced phosphorylation of GCN2 and eIF2α in HTR8/SVneo cells.
J Biol Chem

An inhibitor of GCN2 and the integrated stress response directly targets ZAK protein kinase to limit cytotoxicity. [Abstract]

2026 Jun;302(6):111482. PMID: 42031169
Pharm Res

Regulatory Role of eIF2αK4 in Amino Acid Transporter Expression in Mouse Brain Capillary Endothelial Cells. [Abstract]

2024 Nov;41(11):2213-2223. PMID: 39532778
J Biol Chem

Activation of Gcn2 by small molecules designed to be inhibitors. [Abstract]

2023 Apr;299(4):104595 PMID: 36898579
J Biol Chem

Proteasomal degradation of WT proinsulin in pancreatic beta cells. [Abstract]

2022 Oct;298(10):102406. PMID: 35988641
J Biol Chem

The eIF2 kinase GCN2 directs keratinocyte collective cell migration during wound healing via coordination of reactive oxygen species and amino acids. [Abstract]

2021 Nov;297(5):101257. PMID: 34597669
Life Sci Alliance

An ISR-independent role of GCN2 prevents excessive ribosome biogenesis and mRNA translation. [Abstract]

2025 Mar 3;8(5):e202403014. PMID: 40032489
Mol Biol Cell

PERK protein kinase facilitates keratinocyte collective cell migration by engagement with cell adhesion molecules, independent of its kinase activity. [Abstract]

2025 Sep 24:mbcE25060277. PMID: 40991407
Biochem Biophys Res Commun

GCN2 suppression attenuates cerebral ischemia in mice by reducing apoptosis and endoplasmic reticulum (ER) stress through the blockage of FoxO3a-regulated ROS production. [Abstract]

2019 Aug 13;516(1):285-292. PMID: 31255283
bioRxiv

2026 Apr 23.
bioRxiv

2026 Apr 6.
bioRxiv

2026 Mar 28.
bioRxiv

Environmental Amino Acid Sensing Regulates the Rate of ASC Translation and NLRP3 Inflammasome Assembly. [Abstract]

2026 Jan 20:2026.01.16.699988. PMID: 41648523
bioRxiv

2026 Jan 13.
bioRxiv

A dietary pan-amino acid dropout screen in vivo reveals a critical role for histidine in T-ALL. [Abstract]

2025 Dec 23:2025.12.21.694897. PMID: 41509383
Indiana University

2025 Oct.
Indiana University Indianapolis

2025.
bioRxiv

2025 Oct 17.
bioRxiv

Replating induces mTOR-dependent rescue of protein synthesis in Charcot-Marie-Tooth diseased neurons. [Abstract]

2025 Aug 31:2025.08.26.672367. PMID: 40909707
bioRxiv

RNA triggers chronic stress during neuronal aging. [Abstract]

2025 Aug 5:2025.08.04.668575. PMID: 40799579
bioRxiv

The mevalonate pathway couples lipid metabolism to amino acid synthesis via ubiquinone-dependent redox control. [Abstract]

2025 Aug 12:2025.08.10.669191. PMID: 40832310
SSRN

2025 May 7.
bioRxiv

2025 March 13.
bioRxiv

2024 August 16.
bioRxiv

BRAFV600 and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation. [Abstract]

2024 Dec 20:2024.12.19.629301. PMID: 39763857
bioRxiv

2024 September 13.
bioRxiv

2024 June 28.
Imperial College London

2022 Aug.
Sci Total Environ

Microcystin-LR inhibits testosterone synthesis via reactive oxygen species-mediated GCN2/eIF2α pathway in mouse testes. [Abstract]

2021 Aug 10:781:146730. PMID: 33798882
bioRxiv

2019 Oct 31.
bioRxiv

2019 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (110.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2132 mL

11.0661 mL

22.1322 mL

5 mM

0.4426 mL

2.2132 mL

4.4264 mL

10 mM

0.2213 mL

1.1066 mL

2.2132 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (3.70 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (3.70 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2.5 mg/mL (5.53 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nakamura A, et al. Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proc Natl Acad Sci U S A. 2018;115(33):E7776-E7785. [Content Brief]

[2]. Yuan J, et al. Inhibition of GCN2 Alleviates Cardiomyopathy in Type 2 Diabetic Mice via Attenuating Lipotoxicity and Oxidative Stress. Antioxidants (Basel). 2022;11(7):1379. Published 2022 Jul 16. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2132 mL	11.0661 mL	22.1322 mL	55.3305 mL
	5 mM	0.4426 mL	2.2132 mL	4.4264 mL	11.0661 mL
	10 mM	0.2213 mL	1.1066 mL	2.2132 mL	5.5331 mL
	15 mM	0.1475 mL	0.7377 mL	1.4755 mL	3.6887 mL
	20 mM	0.1107 mL	0.5533 mL	1.1066 mL	2.7665 mL
	25 mM	0.0885 mL	0.4426 mL	0.8853 mL	2.2132 mL
	30 mM	0.0738 mL	0.3689 mL	0.7377 mL	1.8444 mL
	40 mM	0.0553 mL	0.2767 mL	0.5533 mL	1.3833 mL
	50 mM	0.0443 mL	0.2213 mL	0.4426 mL	1.1066 mL
	60 mM	0.0369 mL	0.1844 mL	0.3689 mL	0.9222 mL
	80 mM	0.0277 mL	0.1383 mL	0.2767 mL	0.6916 mL
	100 mM	0.0221 mL	0.1107 mL	0.2213 mL	0.5533 mL

Keywords

GCN2iB

63 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

GCN2iB

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Cancer Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) GCN2iB

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (63)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GCN2iB

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Cancer Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) GCN2iB

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (63)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

GCN2iB Related Classifications

HY-112654 Related Classifications